NK Max "Tripartite Business Agreement with Dankook University Hospital and Others... Healthcare Workforce Training"

[Asia Economy Reporter Hyunseok Yoo] NKMAX, a developer of NK cell immuno-oncology drugs, announced on the 27th that it has signed a tripartite business agreement with Dankook University Hospital and Dankook University I-Dasan LINC+ Project Group to foster and secure healthcare-related technical personnel and promote corporate development.

Through this business agreement, the three parties agreed to actively cooperate in ▲ mutual collaboration on immune testing, immune cell therapy, and bio healthcare, ▲ research cooperation for discovering joint research projects and developing new clinical services, and ▲ joint use of research facilities and equipment.

Kim Jae-il, Director of Dankook University Hospital, said, “We expect to actively interact in clinical services in the future, including reviewing the applicability of cell therapies to diseases such as Parkinson’s and Alzheimer’s,” and added, “We will strive to enhance cooperative relationships across various fields.”

Jang Seung-jun, Director of Dankook University I-Dasan LINC+ Project Group, said, “The project group has been highly evaluated for its efforts to increase connectivity with companies and improve employment rates of enrolled students, achieving excellent results in the Social Customized Industry-Academic Cooperation Leading University (LINC+) fostering project,” and added, “Through this agreement, we will collaborate with NKMAX, which possesses NK cell-related technological capabilities, to contribute to nurturing personnel who will play a pivotal role in regional community development.”

Park Sang-woo, CEO of NKMAX, said, “This business agreement has laid the foundation for tripartite joint development among industry, academia, and hospital,” and added, “We plan to concretize cooperation plans to help not only the company’s growth but also talent development and acquisition.”